3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Unknown
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
24
Neoplasm Metastasis
6
Colonic Neoplasms
6
Stomach Neoplasms
5
Rectal Neoplasms
5
Carcinoma, Hepatocellular
4
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Biliary Tract Neoplasms
3
Adenocarcinoma Of Esophagus
3
Unresectable Metastatic Colorectal Cancer
2
Recurrence
2
Neoplastic Cells, Circulating
2
Neoplasms
2
Gastrointestinal Neoplasms
2
Adenocarcinoma
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Ovarian Neoplasms
1
Oligometastatic Gastric Adenocarcinoma
1
Neoplasms, Second Primary
1
Neoplasm, Residual
1
Margins of Excision
1
Lung Neoplasms
1
Locally-advanced Rectal Cancer
1
Locally Advanced Colorectal Carcinoma
1
Hyperthermia
1
Gastroesophageal Junction Adenocarcinoma
1
Gastroesophageal Adenocarcinoma
1
Gallbladder Neoplasms
1
Interventions
Cyclophosphamide
21
venetoclax
18
pembrolizumab
16
Dexamethasone
16
fludarabine
14
Cytarabine
13
Gemcitabine
9
pomalidomide
8
Rituximab
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
Immunotherapy, Adoptive
7
selinexor
6
Paclitaxel
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Oxaliplatin
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
Folfox protocol
×
Clear all
NCT06475352
2026-04-23
FUDOSE
UNICANCER
Phase 2
Recruiting
400 enrolled
NCT05476796
2024-10-24
LOGICAN
UNICANCER
Phase 2
Recruiting
118 enrolled